Novel Insights from Clinical Practice
Bilateral Hypopyon Uveitis in Chronic Myeloid LeukemiaTyagi M.a · Govindhari V.a · Pappuru R.R.a · Ambiya V.b
aKanuri Santhamma Center for Vitreo-Retina Services, L.V. Prasad Eye Institute, Hyderabad, and bArmy College of Medical Sciences, New Delhi, India
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: A leukemic hypopyon is considered an early sign of central nervous system involvement or systemic relapse. A differential diagnosis of masquerade syndromes should be considered in cases of hypopyon uveitis that are atypical or unresponsive to treatment. We report a case of a 45-year-old man who presented with bilateral hypopyon uveitis and was subsequently diagnosed as having chronic myeloid leukemia. Method: Retrospective case review. Results: A 45-year-old diabetic male presented with diminished vision in both eyes for 10 days. Ophthalmic evaluation revealed rubeosis iridis, hypopyon, and signs of proliferative diabetic retinopathy with panretinal laser photocoagulation scars. He subsequently presented 1 week later with a bloodstained hypopyon in his right eye and a persistent hypopyon in his left eye. A peripheral blood smear and subsequent bone marrow trephine biopsy confirmed the diagnosis of chronic myeloid leukemia in blast crisis and he was referred to an oncologist for further management. Conclusion: A recalcitrant or atypical hypopyon uveitis can be an indicator of a blast crisis or a central nervous system involvement or sign of a relapse in cases of leukemia. The presence of unusual bloodstained hypopyon helped in identifying the presence of chronic myeloid leukemia and aided in a prompt oncology consultation.
© 2017 S. Karger AG, Basel
- Kincaid MC, Green WR: Ocular and orbital involvement in leukemia. Surv Ophthalmol 1983;27:211-232.
Decker EB, Burnstine RA: Leukemic relapse presenting as acute unilateral hypopyon in acute lymphocytic leukemia. Ann Ophthalmol 1993;25:346-349.
- Ramsay A, Lightman S: Hypopyon uveitis. Surv Ophthalmol 2001;46:1-18.
- Ayliffe W, Foster CS, Marcoux P, et al: Relapsing acute myeloid leukemia manifesting as hypopyon uveitis. Am J Ophthalmol 1995;119:361-364.
- Santoni G, Fiore C, Lupidi G, et al: Recurring bilateral hypopyon in chronic myeloid leukemia in blastic transformation. A case report. Graefes Arch Clin Exp Ophthalmol 1985;223:211-213.
- Lipton JH, McGowan HD, Payne DG: Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia. Leuk Lymphoma 1995;20:161-163.
- Sudharshan S, Kumari A, Biswas J: Bilateral hypopyon as the presenting feature of chronic myeloid leukemia. Ocul Immunol Inflamm 2008;16:244-246.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.